Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease.

[1]  D. DeMets,et al.  Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[2]  G. Lip,et al.  Current practice of antiarrhythmic drug therapy for prevention of atrial fibrillation in Europe: The European Heart Rhythm Association survey. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[3]  N. Freemantle,et al.  Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses. , 2011, Journal of the American College of Cardiology.

[4]  Nick Freemantle,et al.  Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[5]  G. Naccarelli,et al.  Increasing prevalence of atrial fibrillation and flutter in the United States. , 2009, The American journal of cardiology.

[6]  L. Køber,et al.  Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study. , 2009, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[7]  Kevin J. Anstrom,et al.  Using Inverse Probability-Weighted Estimators in Comparative Effectiveness Analyses With Observational Databases , 2007, Medical care.

[8]  Samuel Wann,et al.  [Guidelines for the management of patients with atrial fibrillation. Executive summary]. , 2006, Revista espanola de cardiologia.

[9]  Silvia G Priori,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit , 2006, Journal of the American College of Cardiology.

[10]  S. Mouly,et al.  Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. , 2006, Archives of internal medicine.

[11]  R. Califf,et al.  Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease , 2006, Circulation.

[12]  D. Wyse,et al.  Comparison of management patterns and clinical outcomes in patients with atrial fibrillation in Canada and the United States (from the analysis of the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] database). , 2005, The American journal of cardiology.

[13]  D. Reda,et al.  Amiodarone versus sotalol for atrial fibrillation. , 2005, The New England journal of medicine.

[14]  Stephen R Cole,et al.  Adjusted survival curves with inverse probability weights , 2004, Comput. Methods Programs Biomed..

[15]  Affirm Investigators.  Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. , 2003, Journal of the American College of Cardiology.

[16]  D. Wolbrette.  Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. , 2003, The American journal of cardiology.

[17]  M. Josephson,et al.  Variation in the utilization of antiarrhythmic drugs in patients with new-onset atrial fibrillation. , 2003, The American journal of cardiology.

[18]  Bertram Pitt,et al.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.

[19]  V. Fuster,et al.  Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. , 1996, Circulation.